XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial

On Friday, the stock price of Xenon Pharmaceuticals (XENE) plummeted after the company announced a pause in new patient enrollment for its clinical trials of azetukalner. The biopharmaceutical firm revealed emerging reports of adverse neuropsychiatric side effects during patient monitoring, a setback for its lead drug candidate in the treatment of major depressive disorder.

As a result, the Relative Strength Index (RSI) for XENE shares fell into the early teens, signifying extremely oversold conditions. Currently, the stock is trading approximately 40% below its year-to-date high. Despite this decline, Bank of America considers XENE shares a "generational entry point" in U.S. bonds. Mark Cuban, however, shared that he suffered from dizziness for months and built a VR fix to alleviate the issue. JPMorgan has halted its Iran war endgame forecasting due to uncertainty surrounding the situation.